At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Orforglipron (drug), Placebo (drug)
- How long the study runs
- Study runs about 68 months (dates as stated)
- About the drug or intervention
- Orforglipron — drug: Administered orally · Placebo — drug: Administered orally
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 50 Years and over
- Who
- All
- Number of participants
- 7,140
- Started
- 2025-12-01
- Last checked
- 2026-10
Plain English Summary
What is this study?
- • Testing a new treatment for atherosclerosis cardiovascular disease
- • Phase3 - 7,140 participants
- • The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD)
Who can take part?
- • Ages 50 Years and over
- • Diagnosed with atherosclerosis cardiovascular disease
Where?
- • Birmingham - FutureMeds - Birmingham
- • Blackpool - Layton Medical Centre
- • Bromborough - FutureMeds - Liverpool
- • Newcastle - Futuremeds-Newcastle
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 50 Years and over
- Who can join: All genders
What the study is looking for
- ✓Have established ASCVD and/or CKD
Who cannot take part
- ✗Have type 1 diabetes
- ✗Have had a major heart condition within 60 days prior to screening
- ✗Have New York Heart Association Functional Classification Class IV heart failure
See the full criteria
Where Is This Study? (8 UK sites)
FutureMeds - Birmingham
Birmingham B21 9RY, United Kingdom
Layton Medical Centre
Blackpool FY3 7EN, United Kingdom
FutureMeds - Liverpool
Bromborough CH62 6EE, United Kingdom
Futuremeds-Newcastle
Newcastle NE6 1SG, United Kingdom
Newquay Health Centre
Newquay TR7 1RU, United Kingdom
The Adam Practice
Poole BH16 5PW, United Kingdom
Clifton Medical Centre
Rotherham S65 1DA, United Kingdom
Rame Group Practice
Torpoint PL11 2TB, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT